Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.

Saved in:
Bibliographic Details
Title: Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Authors: Zaryouh H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., De Pauw I; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Baysal H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Melis J; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Van den Bossche V; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels B-1200, Belgium.; Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels B-1200, Belgium., Hermans C; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Lau HW; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Lambrechts H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Merlin C; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Corbet C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels B-1200, Belgium., Peeters M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium.; Department of Medical Oncology, Antwerp University Hospital, Edegem 2650, Belgium., Vermorken JB; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium.; Department of Medical Oncology, Antwerp University Hospital, Edegem 2650, Belgium., De Waele J; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium., Lardon F; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium.; The authors contributed equally., Wouters A; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Campus Drie Eiken, Antwerp 2610, Belgium.; The authors contributed equally.
Source: Cancer drug resistance (Alhambra, Calif.) [Cancer Drug Resist] 2023 Oct 17; Vol. 6 (4), pp. 709-728. Date of Electronic Publication: 2023 Oct 17 (Print Publication: 2023).
Publication Type: Journal Article
Journal Info: Publisher: OAE Publishing Inc Country of Publication: United States NLM ID: 101738710 Publication Model: eCollection Cited Medium: Internet ISSN: 2578-532X (Electronic) Linking ISSN: 2578532X NLM ISO Abbreviation: Cancer Drug Resist Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2578-532X
DOI:10.20517/cdr.2023.62